Can Lilly JAK Olumiant, plagued by side effects, really challenge Dupixent in dermatitis?

26th August 2019 Uncategorised 0

Eli Lilly and Incyte’s Olumiant has run up against safety hurdles in the past. But can those hurdles stop the drugmakers from adding another feather to the drug’s cap, this time in the booming—and increasingly competitive—atopic dermatitis (AD) market, currently run by Regeneron and Sanofi’s Dupixent?

More: Can Lilly JAK Olumiant, plagued by side effects, really challenge Dupixent in dermatitis?
Source: fierce